|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.030 USD | +0.98% |
|
+1.98% | +104.98% |
| Jun. 25 | STAAR Surgical Company Appoints Deborah Andrews as Chief Financial Officer, Effective June 25, 2025 | CI |
| Jun. 24 | Lineage Cell Therapeutics, Inc., Q1 2025 Earnings Call, May 13, 2025 |
Summary: Lineage Cell Therapeutics, Inc.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: Lineage Cell Therapeutics, Inc.
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses: Lineage Cell Therapeutics, Inc.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings Chart: Lineage Cell Therapeutics, Inc.
Source: Surperformance
| Fundamentals (Composite) | Global Valuation (Composite) | Financial estimates revisions (Composite) | Capi.($) | ||
|---|---|---|---|---|---|
| - | - | 235M | |||
| 50.02B | |||||
| 29.65B | |||||
| 28.69B | |||||
| 28.16B | |||||
| 12.7B | |||||
| 11.96B | |||||
| 10.42B | |||||
| Average | 21.48B | ||||
| Weighted average by Cap. |
Investor (Composite)
-
Trader (Composite)
ESG MSCI
-
Financials
Revenue growth
EPS growth
Capital Efficiency (Composite)
-
Net Margin
-
Financial Health (Composite)
-
Valuation
P/E
-
EV/Revenue
-
EV/EBITDA
-
PBR
-
Dividend Yield
-
Revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
Revenue revisions (1 month)
EPS revisions (1 year)
EPS revisions (4 months)
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (4 months)
Analysts' target price evolution (1 year)
Business Predictability
Surprise rates
Analysts' coverage
Analysts' recommendations divergence
Analysts' Target price divergence
Financial estimates divergence
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LCTX Stock
- Ratings Lineage Cell Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
